Although it did not reach statistical significance, patients with early stage disease at presentation (FIGO stage I–II) experienced better survival than patients with advanced stage (FIGO stage III–IV) of disease: median OS 59.7 vs. 33.0 months, respectively (p=0.120, log-rank test).
← all excerpts
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer.
1
—
—